Genomics and multimorbidity.
Genomics and multimorbidity.
复制标题
基因组学和多发病。
DOI：
10.1093/ageing/afac285
复制
发表时间：
2022
期刊：
影响因子：
6.7
通讯作者：
Masoli JAH
中科院分区：
文献类型：
--
作者：
Masoli JAH
多发性疾病在世界范围内的流行率有所上升。预计到2035年，它将影响超过六分之一的英国人口，现在被公认为全球卫生研究的优先事项。在过去的20多年里，基因组医学从第一次人类基因组测序到整合到临床护理中，用于更罕见的条件。基因研究有助于识别新的疾病机制，因为它们不太容易受到影响流行病学研究的偏见和混淆的影响，因为遗传学是从受孕开始分配的。药物的疗效和副作用的风险也存在遗传差异，药物遗传学。基因组学方法有可能提高我们对多种长期疾病/多发病机制的理解，并指导风险、诊断和优化管理的精确方法。在这篇评论中，我们总结了基因组学和基因组学在多发病方面的潜在用途。
Multimorbidity has increased in prevalence world-wide. It is anticipated to affect over 1 in 6 of the UK population by 2035 and is now recognised as a global priority for health research. Genomic medicine has rapidly advanced over the last 20 years from the first sequencing of the human genome to integration into clinical care for rarer conditions. Genetic studies help identify new disease mechanisms as they are less susceptible to the bias and confounding that affects epidemiological studies, as genetics are assigned from conception. There is also genetic variation in the efficacy of medications and the risk of side effects, pharmacogenetics. Genomic approaches offer the potential to improve our understanding of mechanisms underpinning multiple long-term conditions/multimorbidity and guide precision approaches to risk, diagnosis and optimisation of management. In this commentary as part of theAge and Ageing50th anniversary commentary series, we summarise genomics and the potential utility of genomics in multimorbidity.